BL
AVDL

BFSG LLC’s Avadel Pharmaceuticals AVDL Stock Holding History

BFSG LLC’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$5.25K – 677
2024
Q4 		$5.25K Hold
500
– – ﹤0.01% 559
2024
Q3 		$6.56K Hold
500
– – ﹤0.01% 529
2024
Q2 		$7.03K Hold
500
– – ﹤0.01% 509
2024
Q1 		$8.45K Buy
+500
New +$7.45K ﹤0.01% 515

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BFSG LLC's AVDL Position: Q1 2025 in Review

BFSG LLC sold out of Avadel Pharmaceuticals (AVDL) in Q1 2025, closing a stake of 500 shares — an estimated $5.25K sold.

BFSG LLC first reported a position in AVDL in Q1 2024 and held it in 4 quarters. The position peaked at $8.45K in Q1 2024. 175 funds tracked by Wall St. Rank hold AVDL as of Q1 2025.

  • BFSG LLC reported no remaining Avadel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • BFSG LLC sold 500 Avadel Pharmaceuticals shares in Q1 2025, an estimated $5.25K.
  • BFSG LLC first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • BFSG LLC's Avadel Pharmaceuticals position peaked at $8.45K in Q1 2024.
  • 175 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2025.

Based on BFSG LLC's 13F filing for Q1 2025, filed 18 Apr 2025.